| Primary |
| Onychomycosis |
37.3% |
| Product Used For Unknown Indication |
30.4% |
| Fungal Infection |
7.1% |
| Rash |
4.0% |
| Drug Use For Unknown Indication |
2.8% |
| Fungal Infection Of Nail |
2.5% |
| Urinary Tract Infection |
1.9% |
| Nail Infection |
1.6% |
| Zygomycosis |
1.6% |
| Lower Respiratory Tract Infection |
1.2% |
| Nail Tinea |
1.2% |
| Tinea Pedis |
1.2% |
| Contraception |
0.9% |
| Cystitis |
0.9% |
| Fungal Skin Infection |
0.9% |
| Hypertension |
0.9% |
| Osteopenia |
0.9% |
| Tinea Corporis |
0.9% |
| Tinea Infection |
0.9% |
| Antifungal Treatment |
0.6% |
|
| Paraesthesia |
9.5% |
| Weight Decreased |
8.6% |
| Urticaria |
7.6% |
| Quality Of Life Decreased |
6.7% |
| Renal Impairment |
5.7% |
| Dysgeusia |
4.8% |
| Pain In Extremity |
4.8% |
| Rash |
4.8% |
| Rash Generalised |
4.8% |
| Skin Exfoliation |
4.8% |
| Tendon Rupture |
4.8% |
| Tinea Infection |
4.8% |
| Toxic Epidermal Necrolysis |
4.8% |
| Suicidal Ideation |
3.8% |
| Urinary Retention |
3.8% |
| Visual Impairment |
3.8% |
| Vulvovaginal Candidiasis |
3.8% |
| Ageusia |
2.9% |
| Depression |
2.9% |
| Dyspnoea |
2.9% |
|
| Secondary |
| Product Used For Unknown Indication |
19.9% |
| Phaehyphomycosis |
17.9% |
| Onychomycosis |
6.5% |
| Rash |
6.5% |
| Fungal Infection |
6.0% |
| Pyrexia |
4.5% |
| Type 2 Diabetes Mellitus |
4.5% |
| Hypertension |
4.0% |
| Pneumonia Fungal |
3.5% |
| Bipolar Disorder |
3.0% |
| Cryptococcosis |
3.0% |
| Fusarium Infection |
3.0% |
| Trichophytosis |
3.0% |
| Drug Use For Unknown Indication |
2.5% |
| Psoriasis |
2.5% |
| Acarodermatitis |
2.0% |
| Blood Cholesterol Increased |
2.0% |
| Diabetes Mellitus |
2.0% |
| Erectile Dysfunction |
2.0% |
| Hiv Infection |
2.0% |
|
| Tinea Infection |
13.9% |
| White Blood Cell Count Decreased |
13.9% |
| Weight Increased |
8.3% |
| Cerebrovascular Accident |
5.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
5.6% |
| Interferon Gamma Receptor Deficiency |
5.6% |
| Pruritus |
5.6% |
| Rash Erythematous |
5.6% |
| Vision Blurred |
5.6% |
| Acute Generalised Exanthematous Pustulosis |
2.8% |
| Aspartate Aminotransferase Increased |
2.8% |
| Cataract |
2.8% |
| Cholestasis |
2.8% |
| Cutaneous Lupus Erythematosus |
2.8% |
| Dizziness |
2.8% |
| Drug Ineffective |
2.8% |
| Erectile Dysfunction |
2.8% |
| Foetal Exposure During Pregnancy |
2.8% |
| Gallbladder Disorder |
2.8% |
| Gene Mutation |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
41.0% |
| Rheumatoid Arthritis |
9.8% |
| Onychomycosis |
4.4% |
| Prostate Cancer |
4.4% |
| Hypertension |
4.2% |
| Pain |
4.0% |
| Fungal Infection |
3.8% |
| Depression |
3.6% |
| Asthma |
2.8% |
| Prophylaxis |
2.8% |
| Breast Cancer |
2.6% |
| Type 2 Diabetes Mellitus |
2.6% |
| B Precursor Type Acute Leukaemia |
2.4% |
| Diabetes Mellitus |
2.0% |
| Hiv Infection |
2.0% |
| Cardiac Disorder |
1.6% |
| Multiple Sclerosis |
1.6% |
| Smoking Cessation Therapy |
1.6% |
| Ankylosing Spondylitis |
1.4% |
| Antifungal Prophylaxis |
1.4% |
|
| Thrombotic Thrombocytopenic Purpura |
8.2% |
| Drug Ineffective |
6.6% |
| Myocardial Infarction |
6.6% |
| Skin Exfoliation |
6.6% |
| Urticaria |
6.6% |
| Vision Blurred |
6.6% |
| Hyporeflexia |
4.9% |
| Pneumonia |
4.9% |
| Swelling Face |
4.9% |
| Visual Field Defect |
4.9% |
| Vitamin D Decreased |
4.9% |
| Weight Decreased |
4.9% |
| White Blood Cell Count Decreased |
4.9% |
| Wrong Drug Administered |
4.9% |
| Depression |
3.3% |
| Drug Ineffective For Unapproved Indication |
3.3% |
| Headache |
3.3% |
| Myalgia |
3.3% |
| No Adverse Event |
3.3% |
| Pain |
3.3% |
|
| Interacting |
| Contraception |
45.5% |
| Onychomycosis |
45.5% |
| Vulvovaginal Dryness |
9.1% |
|
| Metrorrhagia |
83.3% |
| Vaginal Haemorrhage |
16.7% |
|
